Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial-Reference-Cited by-同舟云学术

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

Published:2012-01 Issue:1 Volume:10 Page:81-89
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:

Author:

DE PAULA ERICH V.,KAVAKLI KAAN,MAHLANGU JOHNNY,AYOB YASMIN,LENTZ STEVEN R.,MORFINI MASSIMO,NEMES LÁSZLÓ,ŠALEK SILVA Z.,SHIMA MIDORI,WINDYGA JERZY,EHRENFORTH SILKE,CHUANSUMRIT AMPAIWAN,

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1538-7836.2011.04549.x/fullpdf

Reference20 articles.

1. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors;Abshire;J Thromb Haemost,2004

2. NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial;Kavakli;Thromb Haemost,2006

3. Single 270 microg kg(−1)-dose rFVIIa vs. standard 90 microg kg(−1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison;Young;Haemophilia,2008

4. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study;Astermark;Blood,2007

5. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven);Kenet;J Thromb Haemost,2003

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Acute Hemarthrosis in Hemophilia (Including Joint Aspiration);Advances in Hemophilia Treatment;2022

2. Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia;Clinical and Applied Thrombosis/Hemostasis;2020-01-01

3. Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy;Molecular Therapy - Methods & Clinical Development;2019-03

4. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia;Journal of Thrombosis and Haemostasis;2018-08-27

5. Recombinant factor VIIa and prothrombin complex concentrates to treat bleeding episodes in hemophilic patients with inhibitors: a Systematic Review;Hematology & Transfusion International Journal;2018-06-04